Clinical trials: CRC, active
Cancer, Breast Cancer
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
This qualitative study seeks to explore the unmet needs of individuals who have recently undergone a cancer diagnosis and completed the acute phase of treatment.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Thyroid Cancer
- Trial name
- Survivorship (NCT06236373)
- Testing
- Focus Groups or Interviews
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Modena and Reggio Emilia
Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
- Trial name
- BOND-4 (NCT07722754)
- Testing
- Cetuximab, Irinotecan, Bevacizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
Anastomotic Leakage
The Value of Early Postoperative Colonoscopy in The Early Diagnosis of Anastomotic Leakage After Surgery for Low Colorectal Cancer
The goal of this clinical trial is to learn whether early postoperative colonoscopy is valuable in the early diagnosis of anastomotic leakage after surgery for low colorectal cancer.The main questions it aims to answer are: 1.
- Trial name
- NCT07588386
- Testing
- electronic colonoscopy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Nanchong Central Hospital
Colorectal Adenoma, Colorectal Carcinoma
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT02965703
- Testing
- Aspirin, Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Colorectal Cancer
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or…
- Trial name
- FUTURE (NCT06722183)
- Testing
- Futibatinib orally administered, Tislelizumab (i.v. 200mg)
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Carcinoma, Polyp
New bioMarkers tO straTIfy cOlorectal caNcer Referrals
The goal of this observational study is to evaluate if a blood test for circulating progastrin (hPG80) and transposable elements (TEs) can accurately predict colorectal cancer (CRC) or polyps in adult patients referred to the…
- Conditions
- Colorectal Carcinoma, Polyp, Colorectal Adenoma
- Trial name
- MOTION (NCT07035691)
- Where
- United Kingdom
- Volunteers
- 582 people
- Sponsor
- Queen Mary University of London
Cancer, Peritoneal Carcinomatosis
Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein).
- Trial name
- FAPeCa (NCT06061874)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer Metastatic
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Nelitolimod is a classC toll-like receptor 9 (TLR9) agonist that binds to TLR9 receptors on myeloid-derived suppressor cells(MDSCs) and helps reshape the tumor microenvironment (TME) and promote antitumor immunity.
- Trial name
- NCT07172282
- Testing
- Nelitolimod
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Pancreatic Cancer, Breast Cancer
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
This project utilizes LRRC15-specific targeted PET radiotracers to perform PET/MR or PET/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15…
- Conditions
- Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT07552467
- Testing
- Specific PET imaging agents targeting LRRC15
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
This phase Ib/II trial investigates the side effects and best dose of LY3214996 when given together with cetuximab alone or in combination with abemaciclib and to see how well they work in treating patients with colorectal cancer…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT04616183
- Testing
- Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Metastatic Colorectal Cancer
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
- Trial name
- alloSHRINK (NCT03692429)
- Testing
- CYAD-101, FOLFOX, FOLFIRI
- Where
- 4 sites in United States, Belgium
- Volunteers
- 49 people
- Sponsor
- Celyad Oncology SA
Endometriosis, Deep Endometriosis
The Association Between Deep Endometriosis and the Occurrence of Colorectal Carcinoma
The goal of this study is to identify the molecular or genetic mechanisms that may predispose patients with bowel endometriosis to an increased risk of colorectal carcinoma.
- Conditions
- Endometriosis, Deep Endometriosis, Bowel Endometriosis, Colorectal Carcinoma
- Trial name
- NCT07386431
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Shared Decision Making, Colonic Polyp
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
Management of unexpected malignant colorectal polyps removed endoscopically can be challenging due to the risk of residual tumor and lymphatic spread.
- Conditions
- Shared Decision Making, Colonic Polyp, Decision Aids, Rectal Polyp
- Trial name
- NCT05776381
- Testing
- Shared Decision Making using a Patient Decision Aid.
- Volunteers
- 110 people
- Sponsor
- Vejle Hospital
Metastatic Colorectal Cancer
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer
- Trial name
- BEVAMAINT (NCT04188145)
- Testing
- Fluoropyrimidine, Bevacizumab
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Cancer
Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer
Acetylsalicylic acid (ASA) seems the ideal colorectal cancer (CRC) chemoprevention agent. Several ongoing trials are testing the effect of ASA as co-therapy in CRC.
- Trial name
- NCT03957902
- Testing
- acetylsalicylic acid
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Colorectal Cancer, Liver Metastasis
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy.
- Conditions
- Colorectal Cancer, Liver Metastasis, LDRT
- Trial name
- NCT06848465
- Testing
- Low Dose Radiotherapy, Short course Radiotherapy, XELOX
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Locally Recurrent Colorectal Cancer
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
- Trial name
- NCT06881537
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Lung Cancer, Lung Diseases
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel…
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
- Trial name
- NCT07026110
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Colorectal Cancer Metastatic, KRAS G12C Mutation
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
This is an open-label, multicenter, single-arm Phase II clinical study, divided into subgroups A and B: Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for…
- Trial name
- cruciall (NCT06959589)
- Testing
- IBI351, cetuximab β combined with FOLFIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.